AZD0305

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/​Refractory Multiple Myeloma

What's the purpose of the trial?

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.

Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
84
Last Updated
2 weeks ago
Patient Screener

Participating Centers

There are 7 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • AZD0305 is a kind of drug called an antibody drug conjugate. AZD0305 targets a protein found on myeloma cells called GPRC5D.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

AZD0305 Monotherapy

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.